Please login to the form below

Eloctate

This page shows the latest Eloctate news and features for those working in and with pharma, biotech and healthcare.

Dupixent drives Sanofi again, but other new drugs are lagging

There was bad news for Genzyme’s blood disorders unit, however. Long-acting haemophilia A drug Eloctate – acquired as part of Sanofi’s $11.9bn acquisition of Bioverativ last year – succumbed ... Sanofi took a hefty 1.8bn charge on its books in

Latest news

EMA clears Novo Nordisk’s long-acting haemophilia A drug

Takeda’s Shire unit already has a long-acting factor VIII product on the market in Adynovate, as does Sanofi with Eloctate from its recent Bioverativ acquisition, Bayer with Kovaltry, and
Sanofi exits R&D pact with Alnylam on rare disease

Haemophilia and other rare blood diseases have become key therapeutic targets for Sanofi in the wake of its acquisition of Bioverativ – which gave it long-acting clotting factor therapies Eloctate and
Sanofi extends growth spurt thanks to Genzyme, Dupixent

While growth for haemophilia treatments Eloctate and Alprolix – acquired as part of Sanofi’s $11.9bn acquisition of Bioverativ last year – remained fairly sluggish, the quarter was marked first sales contribution ... Eloctate and Alprolix grew 4%
Roche gets wider approval for haemophilia drug Hemlibra

Adynovate, Biogen’s Eloctate, Bayer’s Kovaltry and CSL Behring’s Afstyla – with the advantage of being dosed every one, two, or four weeks depending on need, rather than multiple times
Bayer roll-out of haemophilia drug Jivi gathers pace

and Eloctate, and CSL Behring’s Afstyla, uptake hasn’t been as quick as many had hoped, so Jivi is entering a challenging market.

More from news
Approximately 3 fully matching, plus 26 partially matching documents found.

Latest Intelligence

Deal Watch January 2018

s closing price on 19 January), Sanofi gains the marketed products, Eloctate (haemophilia A therapy) and Alprolix (haemophilia B therapy), as well as a pipeline of candidates focused on rare blood ... disorders. During 2016 Eloctate and Alprolix

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.